{"id":"budesonide-plus-formoterol-combination","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Cough"},{"rate":"5-10%","effect":"Oral candidiasis"},{"rate":"5-10%","effect":"Muscle cramps"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Budesonide works by inhibiting the production of pro-inflammatory cytokines, which contribute to airway inflammation. Formoterol, on the other hand, stimulates the beta2-adrenergic receptors in the airway smooth muscle, leading to bronchodilation and improved lung function.","oneSentence":"Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:13.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance and control of asthma symptoms"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT06531798","phase":"PHASE4","title":"Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-19","conditions":"Moderate to Severe COPD","enrollment":150},{"nctId":"NCT05862545","phase":"","title":"Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":250},{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":"Asthma","enrollment":40},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT07318350","phase":"PHASE3","title":"Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-10","conditions":"Moderate Asthma","enrollment":174},{"nctId":"NCT06110403","phase":"PHASE1, PHASE2","title":"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-09-29","conditions":"Copd","enrollment":35},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT05111262","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-16","conditions":"Asthma, Nonadherence, Medication","enrollment":60},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT06895460","phase":"PHASE3","title":"A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-06-20","conditions":"Bronchial Asthma","enrollment":198},{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT04609904","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-01","conditions":"Asthma","enrollment":2187},{"nctId":"NCT05915182","phase":"","title":"Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-07-21","conditions":"Pulmonary Disease, Chronic Obstructive (COPD)","enrollment":218},{"nctId":"NCT05831566","phase":"PHASE3","title":"Expertise Asthma COPD Program with Digital Support","status":"RECRUITING","sponsor":"Franciscus Gasthuis","startDate":"2023-01-31","conditions":"Asthma","enrollment":138},{"nctId":"NCT06597682","phase":"NA","title":"Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03","conditions":"Post-acute Sequelae of SARS-COV-2 Infection","enrollment":632},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":"Airway Inflammation, Asthma","enrollment":42},{"nctId":"NCT06772454","phase":"","title":"To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-01-01","conditions":"Lung Cancer Squamous Cell, COPD","enrollment":60},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT03888131","phase":"PHASE3","title":"Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-07-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":750},{"nctId":"NCT06573164","phase":"","title":"Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-01","conditions":"Rhinitis, Allergic, Asthma","enrollment":60},{"nctId":"NCT06105671","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Formoterol","status":"COMPLETED","sponsor":"Morten Hostrup, PhD","startDate":"2024-01-05","conditions":"Exercise Performance","enrollment":20},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT04835961","phase":"","title":"AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2021-05-01","conditions":"Asthma","enrollment":1037},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT05322707","phase":"PHASE3","title":"BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2022-04-15","conditions":"Asthma","enrollment":1485},{"nctId":"NCT04705727","phase":"PHASE3","title":"Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-08-23","conditions":"Asthma in Children","enrollment":102},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03033758","phase":"","title":"Evaluation of the Effectiveness and Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol in Greek Patients With Asthma During Routine Clinical Practice.","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2017-02-02","conditions":"Asthma, Quality of Life","enrollment":980},{"nctId":"NCT03015259","phase":"PHASE3","title":"Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2016-12-29","conditions":"Asthma","enrollment":1762},{"nctId":"NCT04215848","phase":"PHASE3","title":"As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period","status":"COMPLETED","sponsor":"Hat Yai Medical Education Center","startDate":"2020-04-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT03083067","phase":"NA","title":"Salvational Intervention for Reducing AECOPD Under Severe Air Pollution","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2017-03-20","conditions":"COPD Exacerbation, Air Pollution","enrollment":402},{"nctId":"NCT04078126","phase":"PHASE3","title":"Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":35},{"nctId":"NCT02237508","phase":"PHASE1","title":"A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-09","conditions":"Asthma","enrollment":90},{"nctId":"NCT02631941","phase":"PHASE1","title":"Clinical Study to Evaluate Z7200 Pharmacokinetics Profile","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2016-01","conditions":"Asthma","enrollment":91},{"nctId":"NCT00476099","phase":"PHASE3","title":"Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":828},{"nctId":"NCT01432080","phase":"PHASE2","title":"Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant","status":"TERMINATED","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2011-09","conditions":"Respiratory Tract Infections, Bronchiolitis Obliterans, Cryptogenic Organizing Pneumonia","enrollment":12},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT04663386","phase":"","title":"Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway","status":"TERMINATED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2020-12-10","conditions":"Asthma, COPD","enrollment":29},{"nctId":"NCT01070888","phase":"PHASE4","title":"Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2010-02","conditions":"Exercise Induced Asthma","enrollment":6},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT01253473","phase":"PHASE4","title":"Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2012-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":46},{"nctId":"NCT01787097","phase":"PHASE4","title":"Effect of Symbicort ® on GR in Sputum in COPD","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"Chronic Obstructive Lung Disease","enrollment":31},{"nctId":"NCT04607629","phase":"PHASE3","title":"An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2018-06-20","conditions":"Bronchial Asthma","enrollment":192},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT04520230","phase":"PHASE4","title":"Three Treatment of Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2014-10-31","conditions":"COPD","enrollment":45},{"nctId":"NCT00915538","phase":"PHASE4","title":"Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)","status":"COMPLETED","sponsor":"Western Sky Medical Research","startDate":"2009-07","conditions":"Asthma","enrollment":16},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT02495168","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-01-13","conditions":"Asthma","enrollment":1714},{"nctId":"NCT00159263","phase":"NA","title":"Effect of Symbicort on GR Localisation in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2004-11","conditions":"Asthma","enrollment":10},{"nctId":"NCT02546297","phase":"PHASE4","title":"Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2017-09-15","conditions":"COPD, Bronchiectasis","enrollment":90},{"nctId":"NCT01415518","phase":"PHASE4","title":"Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":581},{"nctId":"NCT00996697","phase":"PHASE4","title":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2006-10","conditions":"COPD","enrollment":23},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT03563001","phase":"PHASE4","title":"Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome, Small Airway Disease","enrollment":80},{"nctId":"NCT03551197","phase":"PHASE4","title":"Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-06-13","conditions":"Pulmonary Disease, Chronic Obstructive, Exercise, Lung Function Decreased","enrollment":50},{"nctId":"NCT03504527","phase":"NA","title":"Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-05-01","conditions":"Asthma-COPD Overlap","enrollment":120},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT03319043","phase":"PHASE1, PHASE2","title":"Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules.","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2017-11-01","conditions":"Cough Variant Asthma","enrollment":120},{"nctId":"NCT03055793","phase":"","title":"Quality of Life Assessment in Greek asthmatIc Patients Treated With the Fixed Dose Combination of Budesonide / Formoterol in Clinical Practice","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2017-03-01","conditions":"Asthma, Quality of Life, Satisfaction","enrollment":1400},{"nctId":"NCT01218399","phase":"NA","title":"Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Asthma","enrollment":10},{"nctId":"NCT01760304","phase":"PHASE4","title":"Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2012-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":5},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01444430","phase":"PHASE3","title":"A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12","conditions":"Asthma","enrollment":12460},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT02934945","phase":"PHASE4","title":"Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2015-09","conditions":"Bronchial Asthma","enrollment":30},{"nctId":"NCT00479739","phase":"PHASE4","title":"CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Asthma","enrollment":700},{"nctId":"NCT01783821","phase":"PHASE2","title":"LIPS-B: Lung Injury Prevention Study With Budesonide and Beta","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-07","conditions":"Acute Respiratory Distress Syndrome (ARDS)","enrollment":61},{"nctId":"NCT01712854","phase":"PHASE4","title":"Effects of Symbicort on the Ventilatory Kinematics","status":"TERMINATED","sponsor":"Columbia University","startDate":"2012-03","conditions":"Chronic Obstructive Lung Disease","enrollment":9},{"nctId":"NCT01921127","phase":"","title":"Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"COPD","enrollment":3000},{"nctId":"NCT02574975","phase":"PHASE4","title":"Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2015-04","conditions":"Asthma","enrollment":80},{"nctId":"NCT01769898","phase":"PHASE4","title":"The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2013-07","conditions":"Bronchiectasis","enrollment":50},{"nctId":"NCT01404013","phase":"PHASE4","title":"Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2012-02","conditions":"Asthma","enrollment":99},{"nctId":"NCT00849095","phase":"PHASE3","title":"Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2009-04","conditions":"Asthma","enrollment":860},{"nctId":"NCT01070784","phase":"PHASE3","title":"A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":328},{"nctId":"NCT02093195","phase":"PHASE2","title":"Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2013-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":40},{"nctId":"NCT01360021","phase":"PHASE3","title":"New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Asthma","enrollment":214},{"nctId":"NCT01839851","phase":"","title":"Hair Cortisol in Asthma or Allergic Rhinitis Treated With Topical Corticosteroids","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2013-05","conditions":"ASTHMA, ALLERGIC RHINITIS","enrollment":60},{"nctId":"NCT01602523","phase":"PHASE3","title":"Effect of Symbicort on Sleep Quality in Patients With Emphysema","status":"UNKNOWN","sponsor":"Temple University","startDate":"2011-03","conditions":"Emphysema, Poor Sleep Quality","enrollment":40},{"nctId":"NCT00839800","phase":"PHASE3","title":"Study to Investigate the Efficacy of Symbicort® SMART.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Asthma","enrollment":2091},{"nctId":"NCT00496470","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":660},{"nctId":"NCT00702325","phase":"PHASE4","title":"Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Asthma","enrollment":311},{"nctId":"NCT00419952","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Asthma","enrollment":742},{"nctId":"NCT01069289","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1293}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"budesonide plus formoterol combination","genericName":"budesonide plus formoterol combination","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles. Used for Maintenance and control of asthma symptoms, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}